NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) — Net Asset Quality Index
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a Net Asset Quality Index of 92.6% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $786.43 Million minus total liabilities of $58.36 Million yields net assets of $728.07 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check NAMS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
NewAmsterdam Pharma Company N.V. Ordinary Shares Net Asset Quality Index Over Time (2020–2024)
This chart shows how NewAmsterdam Pharma Company N.V. Ordinary Shares's Net Asset Quality Index has evolved across 5 annual periods from 2020 to 2024. As of September 2025, the index stands at 92.6%, representing net assets of $728.07 Million against total assets of $786.43 Million USD. See NewAmsterdam Pharma Company N.V. Ordinar current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
The table below presents the year-by-year Net Asset Quality Index for NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see NewAmsterdam Pharma Company N.V. Ordinar market capitalisation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 87.6% | $757.50 Million | $864.62 Million | $107.12 Million | ▲ +4.5 pp |
| 2023 | 83.1% | $288.39 Million | $347.10 Million | $58.70 Million | ▼ -6.8 pp |
| 2022 | 89.9% | $430.07 Million | $478.50 Million | $48.43 Million | ▲ +6.6 pp |
| 2021 | 83.3% | $56.63 Million | $67.99 Million | $11.36 Million | ▼ -7.8 pp |
| 2020 | 91.1% | $127.46 Million | $139.87 Million | $12.41 Million | — |